Details for New Drug Application (NDA): 020131
✉ Email this page to a colleague
The generic ingredient in PROHANCE is gadoteridol. One supplier is listed for this compound. Additional details are available on the gadoteridol profile page.
Summary for 020131
Tradename: | PROHANCE |
Applicant: | Bracco |
Ingredient: | gadoteridol |
Patents: | 0 |
Pharmacology for NDA: 020131
Mechanism of Action | Magnetic Resonance Contrast Activity |
Suppliers and Packaging for NDA: 020131
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131 | NDA | BRACCO DIAGNOSTICS INC | 0270-1111 | 0270-1111-70 | 5 VIAL, PHARMACY BULK PACKAGE in 1 BOX (0270-1111-70) / 50 mL in 1 VIAL, PHARMACY BULK PACKAGE |
PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131 | NDA | BRACCO DIAGNOSTICS INC | 0270-1111 | 0270-1111-85 | 5 VIAL, PHARMACY BULK PACKAGE in 1 BOX (0270-1111-85) / 100 mL in 1 VIAL, PHARMACY BULK PACKAGE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 279.3MG/ML | ||||
Approval Date: | Nov 16, 1992 | TE: | RLD: | Yes |
Expired US Patents for NDA 020131
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Subscribe | ⤷ Subscribe |
Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Subscribe | ⤷ Subscribe |
Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Subscribe | ⤷ Subscribe |
Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription